# XORTX Therapeutics Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/XORTX Therapeutics Inc.).

## Overview

XORTX Therapeutics Inc. is a U.S.-listed pharmaceutical company based in Calgary, Alberta, focused on developing drug candidates for gout and kidney-related diseases. Its pipeline includes clinical and pre-clinical programs targeting purine metabolism and xanthine oxidase pathways across rare and broader renal indications.

## Products & services

• XRx-026 gout program
• XRx-008 ADPKD program
• XRx-101 acute kidney injury program
• XRx-225 diabetic nephropathy program
• VB4-P5 kidney disease program

- **Gout therapies** (25%) — Development programs aimed at treating gout by reducing uric acid production.
- **Polycystic kidney disease therapies** (25%) — Programs focused on autosomal dominant polycystic kidney disease and related renal dysfunction.
- **Acute kidney injury therapies** (20%) — Drug candidates for acute kidney and organ injury associated with viral respiratory infections.
- **Diabetic nephropathy programs** (15%) — Pre-clinical and pre-IND kidney disease programs targeting diabetic nephropathy.
- **Rare and prevalent kidney disease pipeline** (15%) — Earlier-stage kidney disease assets acquired or in development across multiple indications.

- XRx-026 gout program
- XRx-008 ADPKD program
- XRx-101 acute kidney injury program
- XRx-225 diabetic nephropathy program
- VB4-P5 kidney disease program

## Customers

XORTX's customers are primarily hospitals, physicians, and future specialty prescribers that would use its therapies if approved, with commercial focus centered on gout and kidney disease treatment markets. Because the company is still developing its pipeline, its immediate business counterparties are clinical investigators, research partners, regulators, and capital markets rather than end-product buyers.

- **Gout treatment prescribers** (primary) — Physicians and specialists who would prescribe a gout therapy to reduce uric acid and manage flare burden.
- **Kidney disease specialists** (primary) — Nephrologists and renal clinics targeting ADPKD, diabetic nephropathy, and other kidney disease indications.
- **Hospital acute care settings** (secondary) — Hospitals and acute-care providers that may use therapies for kidney injury associated with viral infections.
- **Clinical research ecosystem** (secondary) — Trial sites, investigators, and development partners needed to advance clinical and pre-clinical programs.

- Specialist physicians treating gout and chronic kidney disease
- Hospitals and treatment centers for acute renal injury settings
- Clinical investigators running trials for late-stage programs
- Future specialty pharma distributors and payers, if approved
- Research and development collaborators supporting clinical advancement

## Geography

XORTX is headquartered in Calgary, Alberta, and is listed in the U.S. and Canada, with additional trading access in Frankfurt. Its business is development-stage and therefore geography is defined more by corporate and capital-market presence than by product sales, with clinical and regulatory activity centered in North America.

- Headquartered in Calgary, Alberta, Canada
- Listed on NASDAQ and formerly TSX Venture Exchange
- Additional trading access in Frankfurt
- North American clinical and corporate base
- No disclosed commercial revenue geography

## Strategy

XORTX is building a focused pipeline around kidney disease and gout, using a small number of clinically advanced programs rather than a broad platform. Its strategy is to progress lead assets through development while expanding into adjacent renal indications that share similar biology and market needs.

- **Advance late-stage clinical assets** (short-term) — Clinical progression is the main value driver for a development-stage pharmaceutical company.
- **Broaden renal pipeline** (medium-term) — Adding adjacent kidney disease programs can diversify scientific and commercial risk.
- **Focus on shared disease biology** (long-term) — Programs targeting purine metabolism and xanthine oxidase can create a coherent therapeutic thesis.

- Advance the lead gout program toward clinical milestones
- Progress ADPKD and acute kidney injury assets
- Extend the pipeline into diabetic nephropathy and related renal disease
- Target shared biology around uric acid and xanthine oxidase
- Use focused development to concentrate capital on the highest-value assets

## Risks

XORTX faces the standard risks of a development-stage biopharmaceutical company: clinical trial failure, regulatory delays, and uncertainty in proving safety and efficacy across its pipeline. The company also depends on funding access and continued execution across multiple early- and late-stage kidney programs, while any development issues could materially delay commercialization.

- **Clinical trial failure** [critical] — Drug candidates may not demonstrate sufficient efficacy or safety in human studies.
- **Regulatory delay or rejection** [high] — Advancing a pharmaceutical asset requires multiple regulatory approvals and filings.
- **Financing dependence** [high] — Development-stage biotech typically requires external capital before product sales exist.
- **Pipeline concentration** [medium] — Value is concentrated in a small number of programs tied to related renal and gout indications.

- Clinical failure risk across gout and kidney disease programs
- Regulatory approval risk for new drug candidates
- Funding and dilution risk typical of development-stage biotech
- Execution risk across multiple programs and stages
- Market adoption risk if approved therapies do not differentiate

## Accounting

The company’s financial reporting is shaped by development-stage biotech accounting, where R&D spend, capitalized acquisition costs, and share-based compensation can dominate results. Investors should also watch judgments around interim reporting, fair value of financial instruments, and any impairment or consolidation-related effects from corporate actions.

- **Research and development expense** — Affects reported loss and comparability across periods
- **Share-based compensation** — Increases non-cash operating expense
- **Fair value of financial instruments** — Can create volatility in reported earnings
- **Going-concern assessment** — Important for liquidity and financial statement interpretation

- R&D expense recognition for clinical and pre-clinical programs
- Share-based compensation for employee and consultant awards
- Fair value measurement of financial instruments
- Going-concern and financing-related disclosures
- Interim IFRS estimates and period-to-period comparability

---

*Last updated: 2026-09-28T12:18:44.813460+00:00*